Test injection to keep hepatitis B suppressed
Treatments studied
Part of Digestive system, Infections clinical trials.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) is at least 18.5 and below 35
- You have had chronic hepatitis B for at least 6 months
- Your hepatitis B virus level is suppressed (below the lab’s detection limit) while on antivirals
- You have been on the same hepatitis B antiviral medicine for at least 24 weeks, with no dose changes for 4 weeks
- You can use effective birth control, if applicable
- You agree to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.